Histone modifications associated with biological drug response in moderate-to-severe psoriasis.
María C Ovejero-BenitoAlejandra ReolidPatricia Sánchez-JiménezMiriam Saiz-RodríguezEster Muñoz-AceitunoMar Llamas-VelascoSamuel Martín-VilchezTeresa CabaleiroManuel RománDolores OchoaEsteban DaudénFrancisco Abad-SantosPublished in: Experimental dermatology (2019)
Psoriasis patients presented reduced levels of acetylated H3 and H4 and increased levels of methylated H3K4 compared to controls. Non-significant changes were observed after treatment administration in any of the histone modifications analysed. Nevertheless, significant changes in methylated H3K27 were found between responders and non-responders to biological drugs at 3 months. As 28% of these patients also presented psoriatic arthritis (PsA), the former analysis was repeated in the subsets of patients with or without PsA. In patients without PsA, significant changes in methylated H3K4 were found between responders and non-responders to biological drugs at 3 and 6 months. Although further studies should confirm these results, these findings suggest that H3K27 and H3K4 methylation may contribute to patients' response to biological drugs in psoriasis.